MA47401A - Vaccins anticancéreux à arn - Google Patents

Vaccins anticancéreux à arn

Info

Publication number
MA47401A
MA47401A MA047401A MA47401A MA47401A MA 47401 A MA47401 A MA 47401A MA 047401 A MA047401 A MA 047401A MA 47401 A MA47401 A MA 47401A MA 47401 A MA47401 A MA 47401A
Authority
MA
Morocco
Prior art keywords
cancer vaccines
rna anti
rna
vaccines
cancer
Prior art date
Application number
MA047401A
Other languages
English (en)
French (fr)
Inventor
Ted Ashburn
Kristen Hopson
Nicholas Valiante
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA47401A publication Critical patent/MA47401A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047401A 2017-02-01 2017-10-26 Vaccins anticancéreux à arn MA47401A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762453465P 2017-02-01 2017-02-01
US201762453444P 2017-02-01 2017-02-01
US201762558238P 2017-09-13 2017-09-13

Publications (1)

Publication Number Publication Date
MA47401A true MA47401A (fr) 2021-05-05

Family

ID=63040027

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047401A MA47401A (fr) 2017-02-01 2017-10-26 Vaccins anticancéreux à arn

Country Status (11)

Country Link
US (2) US20190351040A1 (enExample)
EP (1) EP3576751A4 (enExample)
JP (2) JP7731656B2 (enExample)
KR (2) KR20190120233A (enExample)
CN (1) CN110505877A (enExample)
AU (1) AU2017397458B2 (enExample)
CA (1) CA3052255A1 (enExample)
MA (1) MA47401A (enExample)
RU (2) RU2022106357A (enExample)
SG (2) SG10202108307YA (enExample)
WO (1) WO2018144082A1 (enExample)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US12150980B2 (en) 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
CN117731769A (zh) 2015-10-22 2024-03-22 摩登纳特斯有限公司 用于水痘带状疱疹病毒(vzv)的核酸疫苗
MA52645B1 (fr) 2015-10-22 2022-06-30 Modernatx Inc Vaccins contre le virus respiratoire
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MD3386484T2 (ro) 2015-12-10 2022-11-30 Modernatx Inc Compoziții și metode de livrare a unor agenți terapeutici
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
EP4487869A3 (en) * 2016-04-22 2025-07-30 CureVac SE Rna encoding a tumor antigen
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
EP3458034A4 (en) 2016-05-18 2020-01-01 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING RELAXIN
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP3579885A4 (en) * 2017-02-07 2020-12-16 Nantcell, Inc. MAXIMIZING T CELL MEMORY, COMPOSITIONS AND RELATED METHODS
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
EP3813848A4 (en) * 2018-06-27 2022-07-20 ModernaTX, Inc. Personalized cancer vaccine epitope selection
EP3826669A2 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
BR112021006941A2 (pt) 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
JP2022506839A (ja) * 2018-11-07 2022-01-17 モデルナティエックス インコーポレイテッド Ｒｎａがんワクチン
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CA3124837A1 (en) * 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
JP2022521094A (ja) 2019-02-20 2022-04-05 モデルナティエックス インコーポレイテッド 共転写キャッピング用ｒｎａポリメラーゼバリアント
EP3938507A4 (en) 2019-03-11 2023-02-22 ModernaTX, Inc. PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION
CN113905756A (zh) * 2019-03-11 2022-01-07 伊沃逊生物科技股份公司 使用编码新表位的构建体进行核酸疫苗接种
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
CA3134945A1 (en) * 2019-03-25 2020-10-01 Ohio State Innovation Foundation Combination immunoregulation and uses thereof
WO2020242720A1 (en) * 2019-05-02 2020-12-03 University Of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
WO2020243561A1 (en) * 2019-05-31 2020-12-03 Modernatx, Inc. Expanded t cell assay
WO2020247914A1 (en) * 2019-06-07 2020-12-10 Emory University Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN110172480B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用
WO2021038089A1 (en) * 2019-08-29 2021-03-04 Universität Zürich Minimal messenger rnas and uses thereof
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
US20230002799A1 (en) * 2019-12-11 2023-01-05 Vanderbilt University Methods of synthesizing mrna and functional proteins from synthetic double stranded dna
JP2023512072A (ja) * 2020-01-30 2023-03-23 モデルナティエックス インコーポレイテッド 代謝リプログラミングポリペプチドをコードするｍＲＮＡ及びその使用
EP4096708A1 (en) * 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
US20230096704A1 (en) * 2020-02-05 2023-03-30 University Of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
US11912930B2 (en) 2020-03-11 2024-02-27 Advansix Resins & Chemicals Llc Formulation for the recovery of hydrocarbons including a surfactant system
KR20220164506A (ko) * 2020-03-11 2022-12-13 어드밴식스 레진즈 앤드 케미컬즈 엘엘씨 건강관리 제품을 위한 계면활성제
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール
JP2023522249A (ja) 2020-04-22 2023-05-29 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
US11130787B2 (en) * 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
CN115803333A (zh) 2020-07-02 2023-03-14 生命技术公司 三核苷酸帽类似物、其制备和用途
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4194006A4 (en) * 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
EP4196139A2 (en) 2020-08-12 2023-06-21 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
JP7644229B2 (ja) 2020-10-20 2025-03-11 エスティー ファーム カンパニー リミテッド ５’－キャッピングされたｒｎａ合成用オリゴヌクレオチド
WO2022087424A1 (en) * 2020-10-22 2022-04-28 The Regents Of The University Of California Monoamine oxidase blockade therapy for treating cancer through regulating tumor associated macrophages (tams)
WO2022120560A1 (zh) * 2020-12-08 2022-06-16 深圳市瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
WO2022140278A1 (en) * 2020-12-21 2022-06-30 University Of Florida Research Foundation, Inc. Multilamellar rna nanoparticle vaccine against cancer
CN114717229B (zh) * 2021-01-05 2024-09-10 麦塞拿治疗(香港)有限公司 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20240181030A1 (en) * 2021-03-26 2024-06-06 Modernatx, Inc. Pertussis vaccine
NL2028681B1 (en) * 2021-04-02 2022-10-17 Nutcracker Therapeutics Inc Materials and methods for generating antigen-specific t cells and treating diseases
CN113186285B (zh) * 2021-05-10 2022-05-24 深圳市展行生物有限公司 一种辅助诊断胃癌的方法及其使用的miRNA组合
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN113577258B (zh) * 2021-07-31 2024-04-16 山东兴瑞生物科技有限公司 一种双靶点mRNA疫苗及其制备方法
CN115703714B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
IL311302A (en) 2021-09-13 2024-05-01 Oncodna A method for creating a pool of double-stranded DNA encoding tumor neoantigens
EP4147713A1 (en) * 2021-09-13 2023-03-15 OncoDNA A rna vaccine comprising an rna pool generated from a double-stranded dna pool
EP4147712A1 (en) 2021-09-13 2023-03-15 OncoDNA Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
JP2024542173A (ja) 2021-11-09 2024-11-13 アクティム・セラピューティクス・インコーポレイテッド マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN116376942A (zh) * 2021-12-31 2023-07-04 广州国家实验室 mRNA疫苗
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
EP4561602A1 (en) * 2022-07-28 2025-06-04 Stemcell Technologies Canada Inc. Polynucleotides encoding linked antigens and uses thereof
CN115992152A (zh) * 2022-09-22 2023-04-21 浙江大学医学院附属第一医院 一种用于乙型肝炎病毒治疗性mRNA疫苗及其制备方法与应用
EP4600361A1 (en) * 2022-10-07 2025-08-13 University of Tsukuba Design method and production method for nucleic acid construct and protein complex
CN120569481A (zh) * 2022-10-19 2025-08-29 卡利威尔免疫治疗公司 编码可溶性pd-1和il-12的核酸及其用途
WO2024097257A1 (en) * 2022-10-31 2024-05-10 Gritstone Bio, Inc. Combination panel cell-free dna monitoring
EP4612301A1 (en) * 2022-11-03 2025-09-10 ModernaTX, Inc. Chemical stability of mrna
EP4364752A1 (en) 2022-11-07 2024-05-08 OncoDNA Improved vaccine
CN116970614A (zh) * 2022-12-29 2023-10-31 达冕疫苗(广州)有限公司 编码ny-eso-1的核糖核酸疫苗的组合物和方法
US20240238408A1 (en) * 2023-01-17 2024-07-18 The University Of Hong Kong CANCER IMMUNOTHERAPY BY DELIVERY OF mRNA
CN119055671A (zh) * 2023-05-23 2024-12-03 源生生物科技(青岛)有限责任公司 包含miRNA的活性成分及其应用
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna
WO2025080869A1 (en) * 2023-10-11 2025-04-17 The Regents Of The University Of California Pancreatic cancer immunotherapy using cationic lipid and polymer nanocarriers for co-delivery of kras neoantigens and sting and/or other immunomodulators to boost the cancer immunity cycle and treat liver metastasis
WO2025117816A1 (en) * 2023-12-01 2025-06-05 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025153053A1 (en) * 2024-01-17 2025-07-24 Abogen Biosciences (Shanghai) Co., Ltd. Composition and methods for inducing antigen specific immunity against kras mutant cells
WO2025158069A1 (en) * 2024-01-25 2025-07-31 Rheinische Friedrich-Wilhelms-Universität Bonn CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒
CN117883558B (zh) * 2024-03-15 2024-06-14 山东兴瑞生物科技有限公司 靶向肝肿瘤个性化mRNA疫苗的制备方法
CN119874872B (zh) * 2025-01-17 2025-11-25 武汉大学 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
KR102315754B1 (ko) * 2010-05-14 2021-10-22 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
MX360823B (es) * 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
RU2585528C2 (ru) * 2011-08-16 2016-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
SG10201602456WA (en) * 2011-08-31 2016-04-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
DE18200782T1 (de) * 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
CA2898130A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
US20160367651A1 (en) * 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
WO2016011226A1 (en) * 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
WO2016201377A1 (en) * 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
US12150980B2 (en) * 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs
CN114404581A (zh) * 2015-10-22 2022-04-29 摩登纳特斯有限公司 癌症疫苗
RU2765874C2 (ru) * 2016-10-26 2022-02-04 МОДЕРНАТиЭкс, ИНК. Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения

Also Published As

Publication number Publication date
JP2020506189A (ja) 2020-02-27
KR20240117650A (ko) 2024-08-01
RU2019127381A (ru) 2021-03-02
SG10202108307YA (en) 2021-08-30
JP2023164537A (ja) 2023-11-10
CA3052255A1 (en) 2018-08-09
EP3576751A1 (en) 2019-12-11
SG11201906895WA (en) 2019-08-27
JP7731656B2 (ja) 2025-09-01
RU2022106357A (ru) 2022-03-24
AU2017397458A1 (en) 2019-08-15
RU2019127381A3 (enExample) 2021-06-17
CN110505877A (zh) 2019-11-26
KR20190120233A (ko) 2019-10-23
US20190351040A1 (en) 2019-11-21
US20250134978A1 (en) 2025-05-01
EP3576751A4 (en) 2021-08-04
WO2018144082A1 (en) 2018-08-09
NZ755780A (en) 2023-10-27
RU2768829C2 (ru) 2022-03-24
AU2017397458B2 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
MA47401A (fr) Vaccins anticancéreux à arn
EP3876947A4 (en) RNA CANCER VACCINES
MA50253A (fr) Vaccins à arn contre le virus zika
MA46255A (fr) Vaccins anticancéreux
MA47680A (fr) Arn thérapeutique
MA44479A (fr) Arn transrepliquant
DK3393510T3 (da) Zikavirusvaccine
EP3538146A4 (en) INFLUENZA VACCINE
MA42502A (fr) Vaccins contre une maladie infectieuse
EP3478312A4 (en) NANT CANCER VACCINE
MA52645A (fr) Vaccins contre le virus respiratoire
EP3585803A4 (en) PNEUMOCOCCIC CONJUGATE VACCINE FORMULATIONS
DK3609535T3 (da) Hbv-vaccine
EP3700565A4 (en) ADJUVED VACCINES
DK3313436T3 (da) Multivalent pneumokok-konjugatvaccine
DK3262066T4 (da) Genterapi
PL3534945T3 (pl) Szczepionka przeciwko parwowirusowi świń
EP3773649A4 (en) PERSONALIZED CANCER VACCINE
EP3385286A4 (en) VACCINE FANTASY WITH INCREASED IMMUNOGENITY
EP3273989C0 (en) STREPTOCOCCAL VACCINE
EP3560512A4 (en) COMPOSITION OF VACCINE AGAINST ZONA
EP3344286A4 (en) VACCINES AGAINST OVARIAL CARCINOMA
IL266237A (en) Tolerogenic DNA composition
EP3638297A4 (en) BACTERIAL VACCINE
EP3511016A4 (en) Immunostimulant